<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00379262</url>
  </required_header>
  <id_info>
    <org_study_id>NPC-0501 Trial</org_study_id>
    <nct_id>NCT00379262</nct_id>
  </id_info>
  <brief_title>Therapeutic Gain by Induction-concurrent Chemoradiotherapy and/or Accelerated Fractionation for Nasopharyngeal Carcinoma</brief_title>
  <official_title>Randomized Trial to Evaluate Therapeutic Gain by Changing Chemoradiotherapy From Concurrent-adjuvant to Induction-concurrent Sequence, and Radiotherapy From Conventional to Accelerated Fractionation for Advanced Nasopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hong Kong Nasopharyngeal Cancer Study Group Limited</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Hong Kong Anti-Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>hong Kong Cancer Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hong Kong Nasopharyngeal Cancer Study Group Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this clinical study are threefold:

        1. To compare the benefits in cancer control and survival obtained from adding
           induction-concurrent chemotherapy to radiation with those from adding
           concurrent-adjuvant chemotherapy to radiation.

        2. To test whether replacing fluorouracil with Xeloda in combining with cisplatin in the
           chemotherapy plan will maintain or improve further the chemotherapy benefits while
           reducing the duration of hospital stay.

        3. To see if accelerated fractionation radiotherapy can improve the outcome of patients as
           compared with conventional fractionation radiotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. primary objectives include

             1. comparing induction chemotherapy with Cisplatin + 5-Fluorouracil versus adjuvant
                chemotherapy with Cisplatin + 5-Fluorouracil(PF-Pvs P-PF)

             2. comparing induction chemotherapy with Cisplatin + Capecitabine versus adjuvant
                chemotherapy with Cisplatin + 5-Fluorouracil(PX-P vs P-PF)

             3. comparing accelerated fractionation versus conventional fractionation (AF vs
                CF)radiotherapy.

        2. secondary objectives include

             1. comparing induction chemotherapy with Cisplatin + Capecitabine versus induction
                chemotherapy with Cisplatin + 5-Fluorouracil(PX-P vs PX-P)

             2. Comparing concurrent-adjuvant (CA) versus induction-concurrent (IC) chemotherapy
                sequence.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Actual">May 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival, defined as the time to treatment failure at any site or death due to any cause, at 5-year.</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival, defined as the time to death due to any cause, at 5-year.</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall Failure-Free Rate, defined as time to failure at any site)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Loco-regional Failure-Free Rate, defined as time to local or nodal failure)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant Failure-Free Rate, defined as time to distant failure)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of chemotherapy toxicity and acute RT toxicity grade &gt; 3</measure>
    <time_frame>treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to late toxicity (From the date of randomization to the earliest date of late toxicity grade &gt; 3)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">798</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>1A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Concurrent-Adjuvant CRT using P-PF regimen and conventional fractionation radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Concurrent-Adjuvant CRT using P-PF regimen and accelerated fractionation radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction-Concurrent CRT using PF-P regimen and conventional fractionation radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction-Concurrent CRT using PF-P regimen and accelerated fractionation radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction-Concurrent CRT using PX-P regimen and conventional fractionation radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction-Concurrent CRT using PX-P regimen and accelerated fractionation radiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Dose:1000 mg/m2, BD, Day 1-Day 14 Interval: 21 days Cycles: 3 cycles</description>
    <arm_group_label>3A</arm_group_label>
    <arm_group_label>3B</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adjuvant chemotherapy using PF (5-Fluorouracil )</intervention_name>
    <description>Cisplatin 80 mg/m2 IV + 5-Fluorouracil 1000 mg/m2/day IV infusion for 96 hr every 28 days for 3 cycles</description>
    <arm_group_label>1A</arm_group_label>
    <arm_group_label>1B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Induction chemotherapy using PF (5-Fluorouracil)</intervention_name>
    <description>Cisplatin 100 mg/m2 IV + 5-Fluorouracil 1000 mg/m2/day IV infusion for 120 hr every 21 days for 3 cycles</description>
    <arm_group_label>2A</arm_group_label>
    <arm_group_label>2B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologically proven nasopharyngeal carcinoma for primary treatment with radical
             intent

          -  non-keratinizing or undifferentiated type

          -  stage III-IVB (by AJCC/UICC 6th edition)

          -  ECOG Performance status less or equal to 2

          -  Marrow: WBC &gt;= 4 and platelet &gt;=100

          -  Renal: creatinine clearance &gt;=60

          -  Informed consent

        Exclusion Criteria:

          -  Primary treatment with palliative intent

          -  WHO type I squamous cell carcinoma or adenocarcinoma

          -  Evidence of distant metastases

          -  Patient is pregnant or lactating

          -  Prior malignancy except adequately treated basal cell or squamous cell skin cancer,
             in-situ cervical cancer or other cancer for which the patient has been disease-free
             for 5 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne W.M. Lee, F.R.C.R.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Hong Kong</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roger K.C. Ngan, F.R.C.R</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Clinical Oncology, Quen Elizabeth Hospital, Hong Kong</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Center, Sun Yat Sen University</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Clinical Oncology, Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Clinical Oncology, Princess Margaret Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Clinical Oncology, Queen Elizabeth Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Clinical Oncology, Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Clinical Oncology, Tuen Mun Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, Forastiere AA, Adams G, Sakr WA, Schuller DE, Ensley JF. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol. 1998 Apr;16(4):1310-7.</citation>
    <PMID>9552031</PMID>
  </reference>
  <reference>
    <citation>Lee AW, Lau WH, Tung SY, Chua DT, Chappell R, Xu L, Siu L, Sze WM, Leung TW, Sham JS, Ngan RK, Law SC, Yau TK, Au JS, O'Sullivan B, Pang ES, O SK, Au GK, Lau JT; Hong Kong Nasopharyngeal Cancer Study Group. Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group. J Clin Oncol. 2005 Oct 1;23(28):6966-75.</citation>
    <PMID>16192584</PMID>
  </reference>
  <reference>
    <citation>Lee N, Xia P, Quivey JM, Sultanem K, Poon I, Akazawa C, Akazawa P, Weinberg V, Fu KK. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):12-22.</citation>
    <PMID>12007936</PMID>
  </reference>
  <reference>
    <citation>Le QT, Tate D, Koong A, Gibbs IC, Chang SD, Adler JR, Pinto HA, Terris DJ, Fee WE, Goffinet DR. Improved local control with stereotactic radiosurgical boost in patients with nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2003 Jul 15;56(4):1046-54.</citation>
    <PMID>12829140</PMID>
  </reference>
  <reference>
    <citation>Baujat B, Audry H, Bourhis J, Chan AT, Onat H, Chua DT, Kwong DL, Al-Sarraf M, Chi KH, Hareyama M, Leung SF, Thephamongkhol K, Pignon JP; MAC-NPC Collaborative Group. Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys. 2006 Jan 1;64(1):47-56. Review.</citation>
    <PMID>16377415</PMID>
  </reference>
  <reference>
    <citation>Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, Maroun J, Walde D, Weaver C, Harrison E, Burger HU, Osterwalder B, Wong AO, Wong R. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol. 2001 Apr 15;19(8):2282-92.</citation>
    <PMID>11304782</PMID>
  </reference>
  <reference>
    <citation>Twelves C, Boyer M, Findlay M, Cassidy J, Weitzel C, Barker C, Osterwalder B, Jamieson C, Hieke K; Xeloda Colorectal Cancer Study Group. Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma. Eur J Cancer. 2001 Mar;37(5):597-604.</citation>
    <PMID>11290435</PMID>
  </reference>
  <reference>
    <citation>Chua DT, Sham JS, Au GK. A phase II study of capecitabine in patients with recurrent and metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy. Oral Oncol. 2003 Jun;39(4):361-6.</citation>
    <PMID>12676255</PMID>
  </reference>
  <reference>
    <citation>Greene FL, et al. AJCC Cancer Staging Handbook from the AJCC cancer staging manual, 6th ed. New York: Springer, 2002.</citation>
  </reference>
  <reference>
    <citation>Lee AW, Tung SY, Chan AT, Chappell R, Fu YT, Lu TX, Tan T, Chua DT, O'sullivan B, Xu SL, Pang ES, Sze WM, Leung TW, Kwan WH, Chan PT, Liu XF, Tan EH, Sham JS, Siu L, Lau WH. Preliminary results of a randomized study (NPC-9902 Trial) on therapeutic gain by concurrent chemotherapy and/or accelerated fractionation for locally advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2006 Sep 1;66(1):142-51.</citation>
    <PMID>16904519</PMID>
  </reference>
  <reference>
    <citation>Freedman J, Furberg, C, DeMets D. Fundamentals of clinical trials. Springer-Verlag, NY, 1998.</citation>
  </reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 20, 2006</study_first_submitted>
  <study_first_submitted_qc>September 20, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2006</study_first_posted>
  <last_update_submitted>August 13, 2017</last_update_submitted>
  <last_update_submitted_qc>August 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hong Kong Nasopharyngeal Cancer Study Group Limited</investigator_affiliation>
    <investigator_full_name>Dr. ANNE W M LEE</investigator_full_name>
    <investigator_title>Consultant, Dept of Clinical Oncology, PYNEH</investigator_title>
  </responsible_party>
  <keyword>Nasopharyngeal Carcinoma</keyword>
  <keyword>Chemoradiotherapy</keyword>
  <keyword>Accelerated Fractionation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

